Last reviewed · How we verify
NCT04946500: CISTA
Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
trial in Prosthetic Joint Infection in 120 participants. Status unknown.
15 July 2021
Quick facts
| Lead sponsor | University Hospital, Brest |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 15 May 2021 |
| Primary completion | 15 July 2021 |
| Estimated completion | 15 October 2021 |
| Sites | 1 location across France |
Conditions studied
- Prosthetic Joint Infection — all drugs for Prosthetic Joint Infection →
- Staphylococcus — all drugs for Staphylococcus →
Sponsor
University Hospital, Brest
Who can join
Adults 18 to 120, any sex, with Prosthetic Joint Infection or Staphylococcus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The alternatives to the combination of Fluoroquinolone and Rifampicin in prosthetic joint infections (PJI) caused by staphylococcus are currently unclear. Clindamycin is prescribed as dual therapy in this indication, and provides many advantages. We conducted a multicenter retrospective observational study evaluating the efficacy and safety of Clindamycin in prosthetic joint infections due to staphylococcus between January 2013 and December 2019.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04946500
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prosthetic Joint Infection
Currently open trials in the same condition.
- NCT07107685 — Prosthetic Joint Infection : Lessons From Deceased Patients in Critical Care. · recruiting
- NCT06627842 — OsteoArticular Sepsis in Intensive Care unitS · recruiting
- NCT04650607 — Phage Safety Cohort Study · recruiting
- NCT04858217 — Periprosthetic Joint Infections: Diagnostic Accuracy and Cost-effectiveness Analysis of Serum and Synovial Markers · recruiting
- NCT04724603 — Phage Safety Retrospective Cohort Study · recruiting
Other University Hospital, Brest trials
Trials by the same sponsor.
- NCT07526688 — Aerobic Physical Activity and Orofacial Myofascial Pain · NA · not yet recruiting
- NCT07487155 — Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Dis · NA · not yet recruiting
- NCT07417605 — Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiatio · not yet recruiting
- NCT07302074 — Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations a · NA · recruiting
- NCT06441773 — Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated W · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04946500 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Brest
- Last refreshed: 1 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04946500.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing